In an economic analysis and evaluation released by JAMA Network in 2026, researchers used a decision-tree model and the Monte Carlo simulation approach to compare the annual asthma management costs of SMART vs traditional therapy from a U.S. health care payer perspective. The analysis consisted of data from 6 randomized clinical trials from September 1, 2024, to March 13, 2025, yielding 11,988 individuals with moderate to severe asthma who participated. The findings suggest that SMART therapy was associated with modest cost savings and improved health outcomes compared with traditional asthma therapy. Given its cost-effectiveness, demonstrated effectiveness, and strong guideline endorsement, expanding insurance coverage of SMART may reduce asthma-related morbidity while lowering costs to US health care payers.
Read the full research study here.
Read a news article on the study here.